XORTX Therapeutics Inc
XTSX:XRTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
InfuSystem Holdings Inc
AMEX:INFU
|
US |
|
S
|
Siav SpA
MIL:SIAV
|
IT |
XORTX Therapeutics Inc
Non-Reccuring Items
XORTX Therapeutics Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
XORTX Therapeutics Inc
XTSX:XRTX
|
Non-Reccuring Items
-$1.8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Non-Reccuring Items
-$210m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
21%
|
CAGR 10-Years
11%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Non-Reccuring Items
-CA$32.7m
|
CAGR 3-Years
75%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Non-Reccuring Items
-$2.8m
|
CAGR 3-Years
66%
|
CAGR 5-Years
44%
|
CAGR 10-Years
-9%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Non-Reccuring Items
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Non-Reccuring Items
-CA$7.5m
|
CAGR 3-Years
30%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
XORTX Therapeutics Inc
Glance View
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-09-30. The firm is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) due to coronavirus infection. Its lead product candidates are XRx-008, XRx-101 and XRx-225. XRx-008 is a late clinical stage program focused on demonstrating the potential of its therapy for ADPKD. XRx-101 is a program to treat acute kidney injury associated with Coronavirus/ COVID-19 infection, AKI and associated health consequences. XRx-225 is a program for the treatment of T2DN. The company is also working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.
See Also
What is XORTX Therapeutics Inc's Non-Reccuring Items?
Non-Reccuring Items
-1.8k
USD
Based on the financial report for Dec 31, 2025, XORTX Therapeutics Inc's Non-Reccuring Items amounts to -1.8k USD.
